Ranitidine bismuth citrate, an orally administered Histamine H2-receptor antagonist, demonstrates a potent inhibitory concentration (IC 50) of 3.3 µM and exhibits high selectivity towards SARS-CoV-2-infected cells. It is widely utilized as an anti-Helicobacter pylori agent, exhibiting a minimum inhibitory concentration (MIC 90) value of 16 ng/L.
